Gilgamesh Pharmaceuticals is a clinical-stage biotech startup that operates in the mental health treatment market. The company's primary focus is to revolutionize the treatment of mental illnesses by shifting from symptom management to creating rapid-acting and durable therapies that target the root causes of the diseases.

The company's business model is centered around designing new chemical entities (NCEs), which are essentially new drugs that have not been approved by the FDA yet. These NCEs are created to act through proven mechanisms and are optimized for safety, efficacy, and patient accessibility. This means that Gilgamesh is committed to creating drugs that are not only effective and safe but also easily accessible to patients.

Gilgamesh collaborates with leading research institutions in the biotech field, leveraging their expertise and resources to drive innovation. This collaborative approach allows the company to stay at the forefront of biotech innovation, which is crucial in the highly competitive and rapidly evolving biotech industry.

The company generates revenue through the development and commercialization of its NCEs. Once an NCE is approved by the FDA, Gilgamesh can sell the drug to healthcare providers and patients. The company may also generate income through partnerships with other biotech companies or research institutions.

In summary, Gilgamesh Pharmaceuticals is a clinical-stage biotech company that aims to revolutionize mental health treatment by developing new, safe, and accessible drugs that target the root causes of mental illnesses.

Keywords: Biotech, Mental Health Treatment, Clinical-Stage, New Chemical Entities (NCEs), Safety, Efficacy, Patient Accessibility, Collaboration, Research Institutions, FDA Approval.